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The impact of nanotechnology on oncology is revolutionizing cancer diagnosis and therapy and largely improving prognosis.This is
mainly due to clinical translation of themost recent findings in cancer research, that is, the application of bio- and nanotechnologies.
Cancer genomics and early diagnostics are increasingly playing a key role in developing more precise targeted therapies for most
human tumors. In the last decade, accumulation of basic knowledge has resulted in a tremendous breakthrough in this field.
Nanooncology, through the discovery of new genetic and epigenetic biomarkers, has facilitated the development of more sensitive
biosensors for early cancer detection and cutting-edge multifunctionalized nanoparticles for tumor imaging and targeting. In the
near future, nanooncology is expected to enable a very early tumor diagnosis, combined with personalized therapeutic approaches.
1. Introduction
Personalized oncology provides new hopes for reducing
cancer mortality by selectively targeting anticancer drugs to
malignant cells, at the level of the target-sites on the cell
surface and within the tumor microenvironment [1, 2]. Na-
nooncology has succeeded in increasing specificity and effec-
tiveness of cancer treatments, both facilitating drugs uptake
and delivery and reducing systemic toxicity and adverse
events.
Molecular diagnostics based on the development in
sequencing and genotyping of tumor DNA plays a crucial
role in personalized therapy [3]. Mutations are a prerequisite
for tumor development, often found in cell signaling proteins
as a result of deletions/point mutations in gene-coding
regions or in promoter-enhancer sequences, DNA insertions,
copy-number variations, and chromosomal translocations.
However, not every mutation leads to cancer. Somatic
mutations are typically present in the tyrosine kinase (TK)
domains within DNA sequences encoding for growth factor
receptors involved in signaling pathways, that is, the EGFR,
HER2/ERBB2, KRAS, KIT, FGFR, VEGF-R, ABL, PI3K,
mTOR, PDGF-R, and HGFR/MET.The activating mutations
of the EGFR in a subset of patients with advanced non-small-
cell lung cancer (NSCLC) who respond to the EGFR tyrosine
kinase inhibitor (TKI) gefitinib or erlotinib are paradigmatic
[4].
Personalized oncology started with the HER2 antibody
trastuzumab in breast cancer, followed by the BCR-ABL1
inhibitor imatinib in chronic myeloid leukemia (CML) and
EGFR-TKIs and ALK-MET inhibitor crizotinib in NSCLC;
the most recent success is the BRAF inhibitor vemurafenib
in melanoma [1].
The dramatic breakthroughs in the clinical use of TKIs
for cancer treatment depended on the predictive specific
biomarkers. Metastatic colorectal cancers (CRC), expressing
EGFR, allow for predictive response to targeted therapy with
specific anti-EGFR monoclonal antibodies (mAbs) [5, 6];
however, CRC carrying KRAS mutations failed to respond.
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In addition, current cancer immunotherapy is pre-
dominantly based on antitumor specific mAbs [5], after
failure of interleukin-2 (IL-2), and the potentially life-
threatening adverse events of adoptive cell-transfer of
autologous tumor-infiltrating reactive lymphocytes; despite
this, therapy achieved 40% tumor regression in advanced
metastatic melanoma [7].
The checkpoint regulators CTLA-4 and PD-1 expressed
in immune cells were successfully targeted for immunother-
apies: in metastatic melanoma patients the anti-CTLA-4 ipil-
imumab significantly extended the median OS to 10.1m, in
phase III, compared to 6.4m for the control group, enabling
an unprecedented durable tumor regression of 46,6% at
1 y. and 23,5% at 2 y. [8]. Ipilimumab is becoming a first-
line treatment, doubling survival at 1-2 y. in the metastatic
melanoma; its association with anti-PD-1 mAb nivolumab
ameliorated the 2-year survival to 80%, in phase I [9].
Nanotechnology is revolutionizing cancer management,
because it can partially change its diagnosis, clinical course,
and prognosis. The cancer molecular profiling before treat-
ment can be highly prognostic and predictive of therapeutic
responses or recurrence, by allowing the most suitable treat-
ment for each individual cancer to be administrated.
2. Molecular Diagnostics for
Personalized Oncology
Mutations in TK genomic domains of a number of growth
factor receptors were dubbed “driver” mutations, as they
induce malignant transformation. Despite initial successes,
targeted therapy may fail in a proportion of patients, espe-
cially in tumors with driver mutations. Genetic heterogeneity
and insurgence of drug resistance due to secondary muta-
tions, and tumor relapse, may occur, either early or late
during tumor development, in a minority of tumor cell
subclones, which engender insensitivity to the drug and
tumor progression.
Examples are BRAF and MEK mutations in melanoma
[10] or gatekeepermutations of EGFR, such as pT790Mmuta-
tion in NSCLC, that causes reduced drug binding and may
coexist with EGFR pT790M and MET amplification, and the
P13KCA mutation or overexpression of GAS6 ligand and its
homologous receptor AXL [1]. The resistance to EGFR TK
inhibitors in EGFR-mutated NSCLC patients not correlated
to PT790Mmutation is modulated by FAS and NF𝜅B signal-
ing [11].
The understanding of metabolic and signaling pathways
implicated inmost of the encountered resistancemechanisms
is becoming clear, hence allowing development of new
therapeutic approaches.
Advanced melanoma, which is particularly resistant to
chemotherapy and rapidly metastasizes, is representative
of a multidrug resistant (MDR) cancer type. BRAF-V600E
mutations have been found in over 60%of cases ofmelanoma.
Although initially responsive to specific inhibitors, resistance
rapidly develops in the form of mutated gene amplification.
BRAF is a component of MAPK pathway, which relays
proliferative signals, triggered at cell membrane receptors,
through the cytoplasm to the nucleus.
The mitogen-activated protein kinase MEK is also com-
monly overactivated in melanoma; thus, a combination of
BRAF and MEK inhibitors was conceived as dual mecha-
nisms to inhibit the MAPK pathway in BRAF-V600 muta-
tion-bearing melanomas. Monotherapy with vemurafenib or
dabrafenib achieved OR of 57% and 50% and progression-
free survival (PFS) of 6.9m and of 5.1m, respectively, in phase
III clinical trials. Dual-therapy consisting of dabrafenib +
trametinib obtained a good OR of 75% and PFS of 9.4m in
phase II [12, 13]. Nevertheless, failure to respond and dual
resistance to both drugs rapidly developed [14, 15].
Prognostic markers assays are relevant in molecular
diagnostics for many types of leukemia and cancer (Table 1).
Among these, there are the antioncogene TP53, the IGHV
mutations, and the expression of CLLUI in chronic lympho-
cytic leukemia (CLL) and in breast cancer, to predict the
recurrence risk of lymph node-negative tamoxifen-treated
patients, or methods to quantify estrogen levels and expres-
sion of progesterone receptors, HER2 and Ki-67, which also
have prognostic value [1]. Cell surface receptors (EGFR,
HER2, and KIT) are useful targets for therapy, whereas the
cytoplasmic BRAF results are less accessible.
Mutations of surface receptors are often present in
NSCLC. EGFR mutations are in-frame with microdeletions
at exon 19 [16] and rearrangement of the EML4 gene with
parts of the ALK gene results in enhanced proliferation
and transforming activity in vitro [17]. KRAS mutations are
usually in codon 1 or 12, whereas the vast majority of BRAF
mutations correspond to a hotspot transversion mutation
T1799A at exon 15. All the above-mentioned mutations are
key predictive biomarkers for developing effective strategies
of targeted therapy.
The role of noncoding DNA in cancer has revealed
novel types of promising biomarkers. Genetic and epigenetic
biomarkers in cancer management are beginning to affect
prognosis and outcome for most human tumors [18].
2.1. Genetic Oncomarkers in Tumor andMetastasis Detected by
Advanced Genomics. Therapeutic targeting in solid tumors
is primarily based on the identification of cancer-specific
gene mutations [19]. Targeted delivery of drugs specifically
directed to individual tumor cells resulted in successful
treatment of NSCLC displaying EGFR mutations or car-
rying the EGFR-amplified gene. NSCLC patients treated
with gefitinib showed a significant survival increase [20]
whereas patients with small-cell lung carcinoma (SCLC)
failed to respond. Integration of new proteomics assays
for identifying biomarkers with statistical analysis for stan-
dardizing clinical data resulted in the implementation of
personalized medicine, both providing a predictive response
to treatments and indicating the likelihood of adverse events
[21].
NSCLC frequently express genomic mutations in HER2
(28%), BRAF (2–5%), ALK (5%), and KRAS (30%) [22–25].
The response to specific TKIs varies according to tumor
type and genetic makeup. Tyrosine kinases are undergo-
ing evaluation as first-line treatment alone or combined
with chemotherapy and radiotherapy. In NSCLC, FGRG1
amplifications, PK3CA and DDR2 mutations, and ROS1 and
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RET rearrangements [26] increase the number of potentially
treatable patients.
Targeted therapy improved survival in interstitial stromal
gastric cancer presenting KIT mutations and in HER2-over-
expressing breast cancer [1, 2]. In myeloid leukemia, specific
KIT-driven mutations in codon 822 are predictive of a
positive response to imatinib, while other mutations require
different treatments [27]. Everolimus therapy resulted in
longer remission in the 5% of patients with advanced bladder
cancer carrying a TSC1 gene mutation [28].
Molecular diagnostics now employs next-generation
DNA sequencing [29], that is, oligonucleotide arrays, to
reveal transcription profiling and large-scale single-nucleo-
tide polymorphism assays to detect DNA deletions or ampli-
fications [3]. The latest assays for sequencing the complete
genome and nanopores [30] are specifically adapted to the
clinical requirements, characteristic of a particular cancer.
DNAs or RNAs, cDNAs, miRNAs, and small RNAs are
specifically selected through novel techniques for genome
resequencing and genetic variation. Sequencing of the com-
plete sets of exons of the entire exome in a genome by
target-capture hybridization identifies common and rare
variants, along with infrequent mutations that are predis-
posing to cancer. Genome-wide-association studies (GWAS)
have enabled investigation of sequence variations, which
occur in chromosomal regions from different individuals,
and the detection by chip-basedmethods of single-nucleotide
polymorphisms in the human genome [2].
This has facilitated innovative approaches concerning the
genesis of cancer and allowed the discovery of BRCA1-2 gene
mutations, known to predispose to cancer [3]. Stromal cells
are involved in the genesis and regulation of metastasis [31].
Translation of recent discoveries in metastatic cells and their
interactions with the stromal cells is required to bypass the
main obstacles in cancer therapy [32].
The microenvironment plays a role in renormalization
of tumor cells, suggesting that the recovery of normal func-
tions of stromal cells may be an advantageous strategy in
cancer treatment [33]. Tumor suppression achieved by the
microenvironment of embryonic stem cells has highlighted
new potential therapeutic targets [34].
Expression profiling of genes involved in cell-cell and cell-
matrix contacts has identified changes involved in metas-
tasis. WNT, Notch, and BMP pathways regulate the dor-
mancy of metastasis [35] and GATA3 inhibits metastasis via
miRNA-29b expression [36]. In preclinical models, miRNA-
126 promotes breast cancer metastasis affecting the tumor
microenvironment [37]. Investigating the epithelial mes-
enchymal transition (EMT), and gene expression changes
during transition [38], has enabled the understanding of
the modulation of genes involved in ECM remodeling, cell
adhesion, inflammation, oxidative stress, BMP, and TGF-𝛽
and metastasis. This led to the exploration of other adverse
events that facilitate malignancy, invasion, and migration,
characteristic of tumors with cancer stem-cell- (CSC-) like
phenotype, which promotes EMT [39].
EMT promotes resistance to chemo- and radiotherapy;
hence, its elucidation has opened the way to therapeutic
manipulation of the most aggressive cancers. A robust
EMT-signature was developed to predict resistance to EGFR
and P13K/AKT pathway inhibitors in NSCLC patients [40]
in whom erlotinib-resistance was dependent on AXL-kinase
activation [41]. AXL-inhibitor SGI-7079 reverses erlotinib-
resistance.
2.2. Targets in Cancer Stem Cells. CSC are a stable cell pop-
ulation, whose origin is still a source of fierce debate, and
their golden standards are self-renewal in vitro and in vivo,
preserving a constant reservoir. CSC both interact with the
tumor microenvironment and ensure to themselves changes
that are the ideal niche for their preservation and continuity
overtime. Although present in small number in the tumors,
CSC show even within the same tumor a heterogeneity
that depends on the stage, the degree, and the level of
differentiation. CSC act as tumor initiating cells (TIC) and are
involved in metastasis and in mediating tumor progression
and relapse. A number of markers have been defined that
enabled the isolation and characterization of CSC exhibiting
different phenotypes in diverse types of tumors [42, 43] allow-
ing targeting therapies [44]. CSC are highly carcinogenic
and very resistant to conventional anticancer chemotherapy
and radiotherapy [45]; hence, specific targets are mandatory
for directing anticancer agents for effective therapies to
successfully eradicate cancers. CSC are mainly involved in
resistance: to DNA damage induced by high levels of DNA
repair [46], to drug penetration, by enhanced expression of
ATP-binding cassette drug transporters [47], and to apoptosis
[48].
The location of CSC in “niches” of the microenvironment
and hypoxia protects them from anticancer agents [49]. Vari-
ous signaling pathways of normal stem cells are also required
for the maintenance of CSC renewal in different human
malignancies, such as Hyppo, Hedgehog, Notch, WNT,
and P13K/AKT [45]. Snail transcription factor and TGF-𝛽,
involved in EMT, play a primary role in CSC activation.
VitaminD3 and phytochemicals act on the CSC signaling
pathway, such as green tea catechins and the salinomycin,
which selectively kills breast CSC [50], and provide poten-
tially effective compounds that reduce tumor growth [51].
Chemotherapy that preferentially kills most of the sensitive
tumor cells selects the CSC-subset [52]. New agents specifi-
cally targeting for CSC are actively sought after [48], but not
yet available.
2.3. Searching for Epigenetic Cancer Biomarkers. The long-
term disruption of epigenetic control in cancer cells is due to
reduced levels ofDNAmethylation [53], alteration in histones
or their acetylation [18], and changes in lncRNAs and miR-
NAs [54, 55]. As DNAmethylation is the initial control point
of regulating gene transcription, as well as controlling anti-
oncogene expression and transcription of silencing RNAs
that predispose to cancer, epigenetics is principally implicated
in the induction and maintenance of carcinogenesis [56].
The dependency on epigenetic alterations, such as changes
in DNA methylation, for the survival of cancer cells, is well
known and demonstrated in vivo in preclinical cancermodels
[18]. In the majority of cancers, loss of DNA methylation is
6 Journal of Nanotechnology
prevalent; converselyCpG islands of tumor suppressing genes
(TSGs) are hypermethylated, leading to their silencing [57].
Silencing of regulatory genes has been suggested as
alternative to mutations that impair genes structures or
inactivate their functionality. Silencing of BRCA1-2 in ovarian
and breast carcinomas, and of CDKN2A in squamous cell
lung cancer, is typical and supports the “two-hit” hypothesis
of Knudson that requires a mutation in both TSGs alleles for
their silencing to produce a tumorigenic phenotype [58].
The first evidence for the involvement of miRNA in
cancer was revealed by the discovery of frequent deletions of
miRNA-15 and miRNA-16 in chronic lymphocytic leukemia
(CLL) [59].
Epigenetic personalized medicine has advanced cancer
therapy [60]. Epigenetic alterations are increasingly being
discovered. Such alterations affect chromatin and gene
expression, via DNA methylation, histone acetylation, and
deacetylation (e.g., HDAC), respectively, silencing and reac-
tivating gene expression. Indeed, HDAC and DNA methyl-
transferase (DMNT) inhibitors are successfully employed
in MDS and various forms of leukemia [60]. Epigenetic
biomarkers have greatly enhanced cancer detection and diag-
nosis (Table 1), such as for skin [61, 62], oral squamous cell
carcinoma (OSCC) [63], prostate [64], gastric [65], colorectal
[66], liver [67], ovarian [68], cervical [69], breast [70],
bladder [71], respiratory tract [72], and lung [23] cancers.
In addition to TSGs, DNA methylation may also silence
genes implicated in cell growth, regulation, and differentia-
tion: hundreds of methylated genes have been reported in
human cancers, associated with poor disease outcome and
clinical response [73]. New methods for DNA methylation
fingerprinting have enabled growth of epigenetic marks;
nonetheless, very few methylated genes are utilized as cancer
biomarkers in diagnostics [74]. Epigenetic modifications in
BRAF andRAS genes are frequently observed in deregulation
of the MAPK signaling pathway that drives melanoma and
can therefore be utilized as genetic cancer biomarkers [75].
Abnormal DNA methylation, histone modifications, and
impaired expression of induced miRNAs drive OSCC [76]
presenting MLH1 mutations and hypermethylation and
silencing of MGMT and RASSF genes. Hypermethylated
HS3ST2, NPY, and HOXA9 genes allow early detection of
OSCC, while epigenetic deregulation of NOTCH4 identifies
disease recurrence [63].
Genetic and epigenetic changes that occur at different
steps in normal cells [18] cooperatively determine the “hall-
marks of cancer” leading to malignant transformation [77].
The extraordinary variability of prostate cancer observed
by large-scale genomic studies is exemplary of molecular
features required for stratifying patients into subgroups for
predicting the outcome and selecting the most appropriate
therapy. Gene expression profiles and related functional
therapeutic information define the best therapy [64].
Prostate cancer frequently presents mutations, such
as deletions in TSGs, NKX3-1, PTEN, BRCA2, and RB1,
and structural genomic rearrangements which may lead
to recurrent fusion of the androgen-responsive genes for
TMPRSS2 and transcription factors (TFs). This tumor sub-
type is androgen-independent, displays a more aggressive
phenotype, and has an unfavorable prognosis [3]. Several
point mutations have been identified in high-risk prostate
cancer patients, providing information on the mechanisms
that promote genetic instability and on the routes through
which specific genes and associated pathways may function
as potential targetable biomarkers for new therapies.
CRC is a paradigmatic example of tumor progression
toward full malignancy, in which both genetic and epigenetic
markers have been identified [78]. Comparative sequence
analysis of adenomas, the most frequent precancerous lesion
for adenocarcinomas, suggests that mutations arise primarily
affecting genes and pathways that control cellular growth and
differentiation and transform normal cells into carcinomas
capable of metastasis [79]. The WNT pathway is involved
in the adenoma-carcinoma-transition, and an inverse rela-
tionship has been observed between WNT and the APC
gene, which is involved in early transformation to adenomas
and is mutated in about 80% of CRC. APC mutations result
in constitutive activation of WNT signaling. In CRC, other
mutated oncogenes include KRAS and BRAF, which increase
cell proliferation to the same extent as APC mutations, but
mutations also occur in SMAD4 and TGFBR2 genes or as
18q locus deletions. Loss of TGF-𝛽 signaling transforms the
intermediate differentiated adenoma into a full adenoma
and drives late events in tumor development, including
mutations in TP53, present in 50% of CRC. Most CRC occur
sporadically; however, they may also arise due to genetically
transmitted mutations or following inflammatory bowel dis-
ease. Subtypes are defined according to molecular features
based on the tumor epigenetic traits, namely, microsatellite
instability (MSI), chromosomal instability (CIN), MLH1 pro-
moter methylation, and CpG dinucleotide island methylator
phenotype (CIMP) [18]. All three subtypes carrymutations in
protein-coding genes in addition to impaired gene functions,
and changes in miRNA expression affecting gene expression.
In HCC significant differential methylation has been
revealed by genome-wide methylation profiling and pyrose-
quencing analysis [80]. Large-scale screening of differentially
methylated regions in promoter CpG islands has shown that
the changes in methylation particularly affect the signaling
networks of BMP4, CDKN2A, GSTP1, and NFATC1, which
are all involved in cell development, expression, and death.
A genetic basis for epigenetic disruption in cancer has
been universally recognized. It is thus reasonable to assume
that disruption of epigenetic control by mutations of key
regulators of the extensive transcriptome amplifies the effect
of a single genetic alteration. Large-scale sequencing of
HCC has revealed mutations in epigenetic regulators, both
associated and unassociated with HBV and HCV infections
[81]. Mutated genes, most leading to loss of gene function,
have been found in nearly allHCC cases [82]. Pointmutations
and microdeletions were infrequent in the control genes
TP53, CDKN2A, and AXIN1, with the exception of CTNNB1,
encoding 𝛽-catenin. Epigenetic alterations in TP53 and
CTNNB1 genes offer new therapeutic targets and biomarkers;
for example, for the deregulated expression of the regulatory
gene EZH2 involved in epigenetic silencing of the WNT/𝛽-
catenin pathway and of TSGmiRNA, the former is associated
with progression and aggressive phenotype and the latterwith
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prometastatic evolution of HCC. Expression of specific miR-
NAs is also associated with HCV-related HCC-pathogenesis
[83], the molecular network of which includes TSGs, namely,
TP53, PTEN, and all-trans-RA, whose disruption is directly
involved in tumor development.
Cervical carcinoma is another type of cancer associated
with viral infection, in which recurrent somatic mutations of
the MAPK1 gene are particularly relevant and may be indica-
tive of ERBB2 activation suggesting that selected cervical
carcinoma patients could therapeutically benefit fromERBB2
inhibition [69]. Gene expression levels in HPV integration
sites are significantly higher in tumors with HPV integration.
Both hypermethylation and mutation of the TSG necdin
(NDN)were detected inmost primary urothelial carcinomas,
accompanying loss of NDN expression [84]. A total of 50%
of transitional bladder cancers show genetic aberration of
chromatin-remodeling genes, amongwhichUTX is preferen-
tially altered in low-stages and low-grades cancers, providing
implications for classification and diagnostics [85]. In lung
adenocarcinomas, chromatin patterns change according to
development and progression of the disease [86]; therefore,
defining chromatin patterns according to the lung adeno-
carcinoma lifecycle would provide new reliable epigenetic
biomarkers in diagnosis, prognosis of tumor progression, and
therapy.
2.4. Novel Emerging Cancer Biomarkers. Protooncogenes
play a very important role in growth and development of
normal cells; they can, however, mutate and undergo abnor-
mal activation, which progress towards carcinogenesis. This
observation led to the discovery of driving mutations in a
number of tumors. Among the mutations in several known
oncogenes [87] and antioncogenes acting as TSGs, such
as TP53 [88], those located in the PK domains of EGFR,
HER2, KIT, FLT3, DMNT (3A and 1), and KRAS GTPase are
particularly relevant [60].
In leukemia, chromosomal translocations leading to
fusion genes with altered gene function are typical (Table 1).
The fusion gene BCR/ABL is formed of the BCR region of
chromosome 22 with c-ABL of chromosome 9; it occurs
in nearly all CML patients and in 20% of patients with
ALL and constitutively activates ABL kinase. Imatinib, which
specifically blocks BCR-ABL enzyme inhibiting ALB kinase
activation, is one of the greatest successes achieved in CML
therapy. In Burkitt’s lymphoma, specific translocation of the
c-Myc gene (8:14) occurs, leading to increased expression
of target genes and inhibition of NF𝜅B pathway genes [3];
in another non-Hodgkin lymphoma, mutations affect NF𝜅B
via CARD11 gene expression. Therefore, drugs specifically
targeting NF𝜅B have been developed, such as bortezomib
(a proteasome inhibitor) considered the first effective treat-
ment against relapsed and refractory lymphoma, along with
chemotherapy.
Transforming genetic fusions have also been recently
reported for several solid malignancies and colon adenocar-
cinomas [89, 90] representing promising targets for clinically
untreatable cancers.
A subset of glioblastomas, containing the transforming
fusion gene involving the TK domain of FGFR and the
transforming acid coiled-coil domain of TACC [91], can
be treated with FGFR kinase inhibitors which corrects the
aneuploidy; in mice harboring intracranial FGFR-TACC-
3, oral administration of an FGFR TKI inhibits glioma
development [92]. Translocations fusing the EGFR coding-
region to several partners have been frequently found in
glioblastoma as functional fusion gene [93]. EGFR-SEP14
fusions activate STAT3 signaling and confer sensitivity to
EGFR inhibitors and independence to mitogens.
Genome-wide sequencing has identified four subgroups
within medulloblastoma (the major cause of death from
childhood cancer), characterized by unique targetable so-
matic copy-number aberrations (SCNAs) involving tandem
duplication of the SNCAIP gene, recurrent translocations
occurring through chromothripsis-like process and leading
to PVT1-MYC and PVT1-NDRG1 fusions, and recurrent
targeting of TGF-𝛽 and NF𝜅B signaling [94].
The prognostic role of theMYCNoncogene amplification
in neuroblastoma cells has been evaluated in numerous
clinical trials [95]. In about 20% of more than 1000 inves-
tigated neuroblastomas, MYCN has been found abnormally
expressed. Since both the status and function of the MYCN
gene and chromosomal aberrations have been reported to
improve risk assessment of patients, it can help selecting the
most appropriate therapy for each subgroup of patients.Using
high density SNP analysis novel drivers of neuroblastoma
development have been revealed, namely, the BARD1 gene
variants, which are a high-risk indicator in carriers [96].
With the advent of GWAS and next-generation sequenc-
ing, allowing the in-depth study of the neuroblastoma
genome, genes associated with tumor progression have been
identified: ALK gene, candidate for therapy with small-
molecule inhibitors; mTOR Aurora kinase and TRKB [95].
The LMO1 locus showed aberrant expression in more than
10%of themost aggressive cases of neuroblastoma, suggesting
that this locus polymorphism is associated with susceptibility
to tumor development and influences malignant progression
[97]. Chromosomal deletions and sequence alterations of
the chromatin-remodeling genes ARID1A-B were found in
10% of neuroblastomas, providing new biomarkers to identify
rearranged DNA fragments in sera allowing for minimal
residual disease detection and therapeutic follow-up [98]. In
addition,methylation of PCDH8 and SFN can be used as out-
come indicators in high-risk patients [99]. In 40% of gliomas,
MGMT, involved in DNA repair, was hypermethylated in the
promoter region [53] and associated with glioma sensitivity
to radiotherapy and alkylating agents. MGMT protects cells
against mutations by removing alkyl groups from guanine.
These are imported with the alkylating agents nitrosamide
5-hydroxymethylcytosine (5HmC), catalyzed by three genes
(TET1–TET3), with 𝛼-ketoglutarate as cofactor, under the
control of isocitrate dehydrogenases IDH1 and IDH2.
Silencing of TET1 bymiRNA leads to a decrease in 5HmC,
while IDH1 and IDH2 mutations have been found in glioma,
myeloid leukemia, andmelanoma andmay therefore serve as
diagnostic markers in a number of cancers [56, 60].
DNA methylation biomarkers are used for early can-
cer detection but can also predict and/or monitor thera-
peutic responses and disease recurrence. Examples include
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the tissue-factor pathway inhibitor 2 (TEPI2), useful for
screening CRC in stools and hypermethylation of septin 9
(SEPT9) in blood samples [79]. In prostate cancer tissue
and urine, DNA methylation biomarkers such as APC or
ENDRB, together with serum prostate specific antigen (PSA)
and quantitative evaluation of glutathione-S-transferase p1
(GSTP1), have improved diagnosis [100, 101].
DNA methylation can be also used as a molecular
prognostic biomarker in stage I NSCLC. Methylation of p16
CDKNZA and H-cadherin (CDK13), RASFIA, and APC was
shown to strongly correlate with early local andmediastinum
lymph-nodal recurrences and short survival [72].
2.5. Toward a Very Early Cancer Diagnosis. Very early detec-
tion of cancer and timely monitoring of recurrence are
of paramount importance in establishing prognosis and
outcome of the disease and, in general, determine the cures
that patients should undergo. Initially, noninvasive diagnostic
tests are carried out, typically the fecal occult blood test
(FOBT) for CRC [78], of blood in urine for bladder or renal
cancer, or hemoptysis for lung cancer. However, all these
symptoms lack specificity, as they are also present in other
pathological conditions. Any positive result requires more
invasive clinical investigations, undesirable for patients, often
posing risks and requiring radiation exposure.
The detection of DNA methylation biomarkers based on
nucleic acids analysis allows for early diagnosis, prognosis,
and prediction of therapeutic response [56]. The discovery
of marker genes of DNA methylation and the understanding
of their role in cancer is leading to the development of
new, more sensitive, and specific genomic-based assays. The
identification of tumor specific DNA methylation at distal
sites from the original neoplasia, such as blood and other
bodily fluids, is particularly suitable for early diagnosis and
clinical management of cancer patients, as it does not require
invasive procedures for sample collection. Two CRC-specific
methylation tests are now commercially available: the plasma
methylated DNA for SEPT9 promoter (ColoVantage) and
the fecal methylated DNA for the methylated vimentin gene
(Colo Sure). DNA methylation markers offer a powerful
diagnostic tool for screening individuals at risk of developing
lung cancer [72].
Circulating DNA, either free or complexed to red blood
cells, platelets, or nucleosomes, has been found in the blood
during the course of various disease states [60] and can
be a very early cancer biomarker, whereas its decrease and
disappearance could be used to monitor the success of
the therapy. One limit comes from that DNA mutations,
epigenetic markers, and signaling pathways require sufficient
material from the affected tissues.
Although promising as noninvasive cancer biomarkers,
analyzing cell-free circulating nucleic acids has not reached
clinical routine. A major hurdle remains which is the detec-
tion sensitivity, even though amplified genomic DNA and
RNA from single cells can be used to characterize rare
circulating cancer cells [102].
Circulating tumor cells (CTC) have been shown to be
responsible for tumor metastasis and resistance to anticancer
therapies. They are indeed highly pathognomonic of the
stage of tumor spread and indicative of metastasis in cancer
patients. New clinical tests using minute quantities of CTC
are ongoing, for early detection at the preneoplastic and/or
premetastatic stage, as for prostate [64] and lung cancers
[103].
Other molecules, such as lipids, carbohydrates, pro-
teins, and smaller metabolite products related to cancer,
can actually be oncomarkers with prognostic value of can-
cer progression, therapeutic response, and disease outcome
[60]. As an example, comparing the emerging biomarkers
from exhaled breath, known as volatile organic compounds
(VOC), and those of exhaled breath condensate (containing
small molecules and nucleic acids) is noninvasive test, allow-
ing a highly specific diagnosis.
SerummiRNAs play a very important role in activation or
suppression of target gene expression (Table 1). Its detection
is minimally invasive; however, it may not be specific for the
indicated cancer [54, 55].
AFP is among the known genetic biomarkers for HCC
[104] (Table 1); in addition, other four potential protein
biomarkers have been identified: ALNL, FLNB, C4A, and
AFT. The first two characterize the HCC group before
treatment better than AFP and provide available screening
biomarkers in other cancers as well [67].
CA9 has been the first reliable diagnostic biomarker of
clear cell renal cell carcinoma (ccRCC) [105]; now, for early
detection of kidney cancer, the urine biomarkers aquaporin 1
(AQP1) and adipophilin (ADRP) [106] and increased plasma
levels of LCP1, NNMT, and NM23A have been evaluated
[107]. Kidney cancer biomarkers play an important role in
determining diagnosis and prognosis and are predictive for
treatment effectiveness and outcome [108], enabling discrim-
ination between the ccRCC and papillary (pRCC) type 1
(with favorable outcome) and type 2 that rapidly metastasizes
[109]. Mucin 1, E-cadherin, VEGF-R2 and VEGF-R3, and
cytokeratins (CK) 20 and 7 are differentially expressed in type
1 and type 2 pRCCs, and alpha-methylacyl-CoA racemase
mRNA is overexpressed in most pRCCs; all are useful
diagnostic biomarkers. CD44, Ki67, CA9, and PCNA, which
play a role in apoptosis, cell cycle, cell migration, and angio-
genesis, offer prognostic value for ccRCCs. Most ccRCCs
bear mutations in the VHL gene [110] that lead to its inac-
tivation or silencing by methylation, causing accumulation
of the transcription factor HIF (hypoxia inducible factor),
hence upregulation of angiogenic and cell proliferation genes.
Overexpressed proteins, such as PDGF and VEGF, are strong
proangiogenic factors and are therapeutic targets that have
led to the first reliable targeted treatments with bevacizumab
and VEGF TKIs [111]. IMP-3 and VEGF-R2 correlate with
poor prognosis in pRCC. IMP3, being expressed 10 times
more in pRCC than in ccRCC, is particularly unfavor-
able and indicates a high risk of developing metastases
[112].
Integrated data analysis of ccRCC evolution toward
malignancy shows a shift in regulation of metabolic pathways
controlled by genetic and epigenetic genes [113].
In RCCs, hypomethylation of DNA and miRNA-21 pro-
moter, mutations in the chromosome 3p21 locus of epigenetic
genes, chromatin remodeling, BAP1, and SETD2 all cause
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inactivation of the TSG PBRM1 and predict an adverse
outcome [114, 115].
In B-cell lymphoma, the serum levels of miRNA-155,
miRNA-210, and miRNA-21 are significantly elevated [116];
miRNA-21 is also associated with prostate cancer [115] and
represents a potential diagnostic biomarker in neoplasia [117].
In most cancers, alterations in chromosomal regions encod-
ing for miRNAs which result in their altered expression have
been reported, pointing to a causal role of miRNAs in cancer
pathogenesis and metastasis [118]. To identify and validate
circulating miRNAs for use as diagnostic and prognos-
tic biomarkers, screening investigations were undertaken,
revealing that high levels of miRNA-21 and miRNA-155 can
be early indicators of lung cancer [119]. miRNA-205 and Lt-
7f can be diagnostic-prognostic biomarkers of ovarian cancer
[120].
Numerous genetic and epigenetic biomarkers that may
accompany lung cancer development, such as miRNAs and
autoantibodies against tumor-associated antigens (TAA), can
be detected up to 5 years before NSCLC diagnosis [121].
Future studies should focus on the identification of miRNA
signatures as biomarkers and on the development of targeted
therapeutics based on miRNAs, as recently attempted for
breast cancer [122]. Circulating regulatory noncoding RNAs,
such asmiRNAs, lncRNAs, and exosomes, are very promising
[123].
Exosomes are nanodimensioned extracellular secreted
vesicles, which are primarily involved in intracellular com-
munications and transport of proteins, lipids, and other cell
components, such as DNA and noncoding RNAs, function-
ing as signaling molecules, between cells. Free or exosome-
encapsulated biomarkers are present in liquid biopsies and
can be detected, even in traces, once concentrated and puri-
fied, or amplified from blood, urine, saliva, and other body
fluids and exudates [124].The latest generation ofmicroarrays
for gene expression profiling and miRNA transcriptomes
has allowed a better assessment of changes in heterogeneity
within and between tumors, for early prediction of thera-
peutic response, establishment of resistance, and metastatic
evolution of the disease.
3. Nanotechnology in Cancer Diagnostics
Routine diagnostics lacks specificity and sensitivity. Engi-
neering of nanoparticles (NPs) to specifically target cancer
cells, combining diagnostic imaging with chemotherapeutic
and/or physical anticancer agents, has facilitated the creation
of multifunctional nanoplatforms for monitoring cancer
therapy [125].
Novel nanodevices convert data from interactions
between molecules and subcellular structures, based on
mutations and alterations in pathways driving cells to
malignant transformation, into transduced or amplified
electromagnetic signals [126, 127]. At the same time, they can
be combined with more effective therapeutic treatments due
to their reduced toxicity, as they only target the transformed
cells [128].
This has been achieved, in the latest biosensors and
nanovehicles (Table 2) [129], utilizing new nanomaterials and
exploiting electric, magnetic, optical, acoustical, mechanical,
chemical, and physical properties of unusual compounds in
order to increase the sensitivity of diagnostic tools and the
effectiveness of the therapeutic devices [130]. In addition,
newly discovered genetic and epigenetic oncomarkers have
been exploited [18] as molecular targets, either for early
cancer detection [131] or for providing more effective and
targeted therapies [132].
Modern nanooncology provides both more accurate
tumor imaging and more efficient therapy by drug delivery
or activation of other anticancer agents, selectively targeted
to cancer cells on the basis of their genetic profile [126].
3.1. Gold, Silica, and Magnetic Nanoparticles. Gold nanopar-
ticles (GNPs) are powerful imaging labels and contrast
agents, due to their unusual optical properties, biocompati-
bility, absence of cytotoxicity, resistance to photobleaching,
and absorbance at near-infrared light region (NIR) of surface-
enhanced Raman scattering (SERS) [133] and have been
successfully used in both cancer diagnosis and therapy [127].
The absorption and scattering properties displayed by GNPs,
conjugated to a ScFv antibody, have been used for in vivo
targeting of EGFR in NSCLC cells, enabling spectroscopic
detection of microscopic tumors.
Recently, plasmon resonance for in vivomolecular imag-
ing of carcinogenesis [134] has been experimentally used
in breast cancer cells, allowing precancerous epithelium
detection and selective photothermal therapy of OSCC
cells by anti-EGFR antibody-conjugated NPs [135]. Gold
nanoparticles combined with gold nanorods conjugated with
specific antibody facilitated extremely sensitive immunoassay
detection of PSA in prostate cancer cells by dynamic light
scattering (DLS) [136, 137].
Metal, magnetic, and silica nanoparticles (SiNPs) present
unique thermophysical properties, such as encapsulated
phase change, which make them particularly suitable for
cancer-specific marker diagnosis [129]. This type of NPs
behaves as a highly sensitive multiplex in oncomarker
detection. Phase-change materials (PCM) are able to absorb
thermal energy without increasing temperature during melt-
ing. Heat diffusion from the environment to the core of
PCM is time-consuming and increases the melting peak at
constant temperature. SiNPs take advantage of the thermic
and physical features of silica, during phase changes. This
allows restriction of any changes in metal composition inside
the silica-encapsulatedNPs, thus providing thermal barcodes
with melting peaks directly related to the concentration
of the target molecules. SiNPs labeled with fluorescence
resonance energy transfer (FRET) dyes have been used
for simultaneous and multiplexed detection in order to
monitor the presence of cancer cells. In preclinical models
of colon carcinoma, the efficient accumulation, in target
tissues, of silica-polyethylene glycol nanoparticles (SPNs)
functionalized with two metastasis-specific peptides results
in specific imaging of tumor foci, providing a powerful
fluorescent platform for image-detection of submillimet-
ric colorectal micrometastases [138]. Aptamer-conjugated
silica NPs specifically target T-cell leukemia and B-cell
lymphoma.
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Magnetic NPs are particularly recommended in cancer
cell imaging to develop diagnostic chips and in therapy to
specifically release drugs within selectively targeted malig-
nant cells [139]. Magnetic NPs are able to aggregate in the
presence of target molecules, facilitating cancer biomarker
measurement. Following surgery, locally implantedmagnetic
NPs can be left in loco; hence, this innovative method for
detecting in vivo cancer biomarkers, such as EGFR and
HER2/neu, may be also suitable for continuous monitoring.
The ability of magnetic particles to aggregate to target
cells via affinity ligands has been exploited as a chip-based
NMR system and, with miniaturization andmultiplexing, for
simultaneously identifying various biomarkers in small liquid
samples.
Magnetic nanosensors are three orders of magnitude
more sensitive than current clinical assays and recent
microchips have been developed that can reveal up to 64
different proteins at the same time.
3.2. Quantum Dots and Carbon Nanotubes. Quantum dots
(QD) are semiconductors composed of light-emitting na-
nocrystals displaying a wide-band adsorption with emission
bands scattered from UV to NIR [140]. QD-conjugated mul-
tifunctional NPs have been successfully used for combining
DOX (doxorubicin) with fluorescent PSMA imaging for
targeting prostate cancer cells [127]. Ultrasensitive nanomi-
crochips, based on QD-labeled antibodies for other specific
biomarkers, such as CEA, CA-125, and HER2/neu, have
been recently developed, enabling oncomarker detection in
serum and saliva. QD-functionalizedmagnetic NPs have also
facilitated cancer targeting and imaging. In this way, it has
been possible to identify and discard CTC from the blood
by magnetic separation, using immobilized biotinylated
EpCAM antibodies targeting malignant cells. In addition,
the ultrasensitive MS-qFRET nanotechnological assay has
been developed to detect and quantify DNA methylation
in blood samples. As DNA methylation is directly involved
in carcinogenesis through silencing of TSGs, this method
can predict the effectiveness of a specific cancer treat-
ment.
Carbon nanotubes (CNT) are helical nanotubes of graph-
ic carbon particularly recommended for label-free detection
of several oncomarkers and, once conveniently modified,
allow a series of extremely specific and sensitive diagnostic
assays, for example, a multifunctional dendrimer-modified
multiwalled CNT for targeting the folic acid (FA) recep-
tor, which is overexpressed in cancer cells, a single-walled
CNT coupled with electrochemiluminescent silica NPs for
detecting PSA in the blood, and, finally, a multilayered
enzyme-coated CNT for high sensitive chemiluminescent
immunoassay of serum AFP. CNT, due to their intrinsic
ability to penetrate the cell membrane in order to release
drugswithin targeted transformed cells and to convert optical
energy into thermal energy, can be exposed to NIR in order
to thermally destroy cancer cells. Conjugation of QD to CNT
has enabled localizing cancer cells in the patients, by QD
imaging, and subsequent cell destruction via drug release or
thermal inactivation [140]. This approach can open up new
horizons on multimodal nanoplatforms in oncology.
3.3. Nanowires and Cantilevers. In2O3 nanowires (NW),
silicon nanowires (SiNW), and gold-conducting polymer
NW (AuNW) can be individually assembled or modified for
detecting cancer biomarkers [127, 129], in particular, SiNWs
for VEGF detection; peptide nucleic acid- (PNA-) modified
SiNW for RNA cancer biomarkers; SiO2-NW IL-10 for
alkaline phosphatase sandwich immune-assay of interleukin-
10; and osteopontin (OPN) lung cancer biomarkers. AuNW
polymers were used as templates for CK-7, epithelial cell
marker, enzymatic immunoassay, and polypyrrole- (Ppy-)
NW, which were integrated into the field effect transistor
(FET) system, as a semiconducting channel for the cancer
antigen 125 (CA 125) assay.
Cantilevers are biosensors for detecting cancer proteins
and DNA/RNA biomarkers, based on nanometer-scale pro-
duced bends, according to changes in their environment or
surface. A cantilever microassay for PSA detection consists
of laser measurement of bend deflection caused by antibody-
antigen specific binding. In this assay, anti-PSA antibody-
conjugation to specific linkers at the microcantilever surface
permits reduction of background signals [129] and allows
measurement of very low antigen concentrations, moni-
toring the surface stress by the reflected laser beam. The
latest microassays for sensing cancer biomarkers have been
developed exploiting resonant microcantilevers, allowing
measurements of shifts in frequency that originate from
antibody-antigen interactions. As decrease in shift depends
on molecular interactions and is proportional to the target
concentration, microcantilevers coated with piezoelectric
film have been developed, which allow exact determination
of CEA concentrations. Another powerful immunological
method using integrated rotating resonancemicrocantilevers
for detecting AFP in undiluted serum at nanogram/mL level
has allowed the investigation of liver cancer at a very early
stage. Nanomechanical analysis for detecting cancer cells in
vivo has been reported, which measures tumor cell-stiffness
with respect to normal cells, by atomic force microscopy.
3.4. Nanopores and Nanorods. Nanopores have great poten-
tial for detecting biomolecules such as DNA, antigens,
ions, and drugs [30]. Nanopores may consist of synthetic
or artificial materials or may be protein-based. They are
based on the principle that ionic conductance changes when
micropores submitted to an electric field are passed through
by small molecules; thus, the electrochemical impedance,
which varies according to the concentration and the nature of
the molecules, can be measured, allowing for the stochastic
sensing and biophysical studies of individual molecules.
Nanopore membrane functionalized with antibodies enables
PSA and hepsin detection while the 𝛼-hemolysin protein
nanopore enables detecting immobilized DNA. Another
possible application of nanopores is the detection of aberrant
DNA methylation by epigenetic analysis [141]. Protein or
synthetic nanopores in Si3N4 membranes have been used
for methylated DNA detection and for ultrarapid DNA
sequencing.
Finally, other ultrasensitive sensors for cancer biomarkers
are the gold nanorods and micropipettes. Gold nanorods
can be used as molecular imaging agent and, in conjugation
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with anti-PSA antibodies, can facilitate DLS analysis for the
PSA immunoassay. Micropipettes, due to the capability of
capturing antibodies on their surface, can be exploited for
detecting IL-10 and VEGF [127].
3.5. Multifunctional Nanoplatforms for Cancer Theranostics.
Over the past twenty years, a prodigious effort has been
made in designing and developing nanometer-sized targeted
probes for cancer diagnosis and therapy, which combine
several features and diverse functions: stability in the cir-
culation, accumulation to specific districts, responsiveness
to local stimuli, and effective intracellular drug delivery
and multimodality of action [127, 130]. Magnetic iron oxide
(ION) nanoparticles used as an MRI contrast agent in
cancer imaging provide morphological details of the tumor
and monitor in real-time the therapeutic response. Highly
lymphotropic superparamagnetic iron oxide nanoparticles
(SPIONs), which at once combine high-resolution MRI
with optical imaging, have been successfully used for
micrometastasis screening in patients with prostate cancer
that have undergone surgical lymph node resection or biopsy
[135].
Recently, multifunctional ultrasmall SPIONs (USPIONs)
based on appropriate and biodegradable coating of N-phos-
phonomethyl iminodiacetic acid (PMIDA) and using func-
tional hydrophilic, biocompatible, and spacer molecules,
such as rhodamine B isothiocyanate, have been designed to
combine cancer-targeted MRI/optical imaging and release
of pH-sensitive drugs [142]. By combining the amine-
derivatized with USPION-PMIDA support, very effective
multimodal and theranostics nanoagents have been pro-
duced, which, when modified with both folic acid and
methotrexate (MTX), simultaneously provide tumor imaging
and intracellular drug targeting and delivery in tumors
overexpressing folic acid receptors (FR) [128].
4. Conclusion
Diagnosis of cancer is often achieved at a late stage when
the adverse effects and drawbacks limit conventional cancer
therapy [126]. Novel molecular biomarkers offer new hope
[143]; for example, miRNAs allow very early, precise, and
innovative cancer diagnosis and therapy and improve prog-
nosis [144, 145]. Customized anticancer treatments started
with specific antitumormAbs andTKIs [5, 6]; however,mAbs
are frequently ineffective as second-line therapy [146], while
TKIs easily engender resistance. To be effective, personalized
oncology requires an anticancer approach at molecular level
specifically directed to a single cancer cell. Hence, compre-
hensive diagnostics of the molecular signature of the tumor
to be treated is essential. Orthotopic tumormodels of patient-
derived xenograft (PDX) in immune-compromised mice
allow predicting drug responsiveness and personalization of
the anticancer treatment [147].
Current nanooncology is focused on satisfying the above-
mentioned diagnostic and therapeutic requirements. It is
based on functionalized nanosensors and biochips for early
and ultrasensitive detection of novel cancer biomarkers [127,
148] and/or on the latest NPs directed to specific cancer
molecular targets, multifunctionalized for diagnostics imag-
ing and targeting therapy [125, 128, 132].
More complex systems have been developed to enhance
drug delivery to key molecular structures in cancer cells and/
or neighboring tissues but also are able to operate as direct
agents themselves, such as for thermal inactivation [149].
Second-generation polymeric nanoparticles have been
approved or are undergoing evaluation. Modification of NPs
facilitates the binding to a large number of cell ligands and
optimizes physicochemical characteristics for drug target-
ing, release, and clearance [150]. The field of cancer thera-
nostics is now dawning. Recently developed nanoparticles,
functionalized to provide multifunctional nanoplatforms in
melanoma [151], are potentially utilizable for many other
cancer types [152, 153], including cancers that present a
stem-cell phenotype [154]. Theranostics, being molecularly
directed, can enable tumor detection at the level of a single
cell(s) and can be simultaneously combined with tumor
diagnostic imaging for monitoring very effective targeted
therapy [155]. Dual diagnostic and therapeutic approach
joined to specific targeting permits a real-time detection of
nanovectors localized at the target-sites and direct visual
appreciation of therapeutic effect on tumor cells, providing
a feedback to diagnosis. To date, it was carried out only in
animal models and cells, displaying a significant reduction
and also the complete disappearance of the tumormass [153].
Undoubtedly in the near future theranostics could provide
the powerful tool for eradicating cancer and metastasis of
any type, at every stage, offering the necessary and alternative
follow-up supporting liquid biopsy, which represents a great
future challenge for early tumor diagnostic.
Liquid biopsies have many clinical applications: the
detection of circulating cell-free DNA (cfDNA) [124], CTC
[64, 103], miRNAs, and exosomes [123]. Although with
differentmodality and variable benefits it permits a very early
and predictive cancer detection, in a noninvasive manner,
through the characterization of the genetic profile of tumors
that, especially under the selective pressure of treatment,
often change their mutation pattern or acquire new muta-
tions.
Very early stage cancer detection helps to reduce mortal-
ity, but this is conceivable only throughwidespread screening,
since most of cancers are at the beginning asymptomatic.
Personalized oncology meets some of major expectations
in diagnostics and therapy. However, genetic heterogeneity,
inside and between tumors and metastasis, together with
the instauration of resistance to antitumor agents represents
the major challenge in targeting therapy of cancer and will
require additional efforts.
At present, there is a lack of standard biomarkers for
cancer diagnosis. Identification biomarkers at a very early
stage of tumorigenesis could be further improved and
other biomarkers specific for particular cancer type require
confirmation. The development of biosensors for detecting
serum biomarkers has provided high sensitive and specific
noninvasive tool, making them extremely promising for use
in early cancer diagnostics. Introduction of nanomaterials
will adjust sensitivity of biosensors in microfluids rendering
them more appropriate for high-throughput assay. In the
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near future, last generation biosensors will help to decrease
mortality rate.
Abbreviations
ABL: Abelson murine leukemic viral oncogene
homolog
ADRP: Adipophilin
AFP: Alpha-fetoprotein
ALK: Anaplastic lymphoma receptor tyrosine
kinase
ALL: Acute lymphatic leukemia
AML: Acute myeloid leukemia
AMACR: Alpha-methylacyl-CoA racemase
APC: Adenomatous polyposis coli
A AQP1: Aquaporin 1
BCR: Breakpoint cluster
BMP: Bone morphogenetic protein
BRAF: v-Raf murine sarcoma viral oncogene
homolog B1
BAP1: BRCA1 associated protein
CA-125: Cancer antigen 125
CDKNZA: Cyclin-dependent kinase
CEA: Carcinoembryonic antigen
cfDNA: Circulating cell-free DNA
CIN: Chromosomal instability
CK: Cytokeratin
CLL: Chronic lymphocytic leukemia
CML: Chronic myeloid leukemia
CIMP: CpG dinucleotide island methylator
phenotype
CRC: Colorectal cancer
CSCC: Cervical squamous cell carcinoma
CSC: Cancer stem cell
CTC: Circulating tumor cells
CTLA-4: Cytotoxic T-lymphocyte antigen-4
DLS: Dynamic light scattering
DNMT: DNA methyltransferase
ECM: Extracellular matrix
EGFR: Epidermal growth factor receptor
EML4: Echinoderm microtubule-associated
protein-like 4
EMT: Epithelial mesenchymal transition
FA: Folic acid
FR: Folic acid receptors
FET: Field effect transistor
FGFR: Fibroblast growth factor receptor
FISH: Fluorescent in situ hybridization
FOBT: Fecal occult blood test
FRET: Fluorescence resonance energy transfer
GNPs: Gold nanoparticles
GSTP1: Glutathione-S-transferase p1
HCC: Human hepatocellular carcinoma
HDAC: Histone deacetylase
HER2/ERBB2: Human epidermal growth factor receptor
ERBB2
HGFR/MET: Hepatocyte growth factor receptor c-MET
HIF: Hypoxia inducible factor
5HmC: 5-Hydroxymethylcytosine
HPV: Human papilloma virus
KIT: v-Kit Hardy-Zuckerman 4 feline sarcoma
viral oncogene homolog
KRAS: Kirsten rat sarcoma viral oncogene
homolog
LMO1: LIM domain only 1
IL-2: Interleukin-2
LCP1: L-plastin, lymphocyte cytosolic protein 1
lncRNAs: Long noncoding RNAs
mAbs: Monoclonal antibodies
MAPK: Mitogen-activated protein kinase
MDR: Multidrug resistance
MDS: Myelodysplastic syndromes
5mC: 5-Methylcytosine
MGMT: O6-Methylguanine-methyltransferase
miRNAs: MicroRNAs
MLH1: mutl homolog 1
MSC: Mesenchymal stem cells
MSI: Microsatellite instability
mTOR: Mammalian target of rapamycin
MTX: Methotrexate
NDN: Necdin gene
NF𝜅B: Nuclear factor kappa B
NIR: Near-infrared light region
NM23A: Nonmetastatic cells 1 protein
NMR: Nuclear magnetic resonance
NNMT: Nicotinamide, N-methyltransferase
NMR: Nuclear magnetic resonance
NPs: Nanoparticles
NSCLC: Non-small-cell lung cancer
OR: Overall response
OSCC: Oral squamous cell carcinoma
PCM: Phase-change materials
PCNA: Proliferating cell nuclear antigen
PD-1: Programmed death-1
PDGF-R: Platelet derived growth factor receptor
PFS: Progression-free survival
PI3K: Phosphoinositide-3-kinase
PMSA: Prostate membrane specific antigen
PSA: Prostate specific antigen
PTEN: Phosphatase and tensin homolog
RA: Retinoid acid
RASSF: RAS-associated domain family
SCC-Ag: Squamous cell carcinoma antigen
SCLC: Small-cell lung cancer
SCNAs: Somatic copy-number alterations
SEPT9: Septin 9
SERS: Surface-enhanced Raman scattering
SNP: Single-nucleotide polymorphism
SPIONs: Superparamagnetic iron oxide
nanoparticles
SiPNs: Silica nanoparticles
SPOP: Speckle-type POZ protein
TEPI2: Tissue-factor pathway inhibitor 2
TGF-𝛽: Tumor growth factor beta
TK: Tyrosine kinase
TKIs: Tyrosine kinase inhibitors
TFs: Transcription factors
TSC1: Tuberous sclerosis complex 1 gene
14 Journal of Nanotechnology
TSG: Tumor suppressor gene
USPIONs: Ultrasmall SPIONs
VEGF-R: Vascular growth factor receptor
VHL: Von Hippel-Lindau
VOC: Volatile organic compounds
WNT: Wingless-related type.
Competing Interests
The authors declare that they have no competing interests.
Acknowledgments
Antonio Ponzetto is a recipient of an unrestricted grant
from Rotfil SpA. The authors are indebted to Dr. Monica
Rinaldi and Professor Bruno Azzarone for critically reading
the paper. They would like to thank Dr. Radhika Srinivasan
for her invaluable help with editing.
References
[1] D. G. de Castro, P. A. Clarke, B. Al-Lazikani, and P. Workman,
“Personalized cancer medicine: molecular diagnostics, predic-
tive biomarkers, and drug resistance,” Clinical Pharmacology
andTherapeutics, vol. 93, no. 3, pp. 252–259, 2013.
[2] H. L. McLeod, “Cancer pharmacogenomics: early promise, but
concerted effort needed,” Science, vol. 340, no. 6127, pp. 1563–
1566, 2013.
[3] T. J. R. Harris and F. McCormick, “The molecular pathology of
cancer,” Nature Reviews Clinical Oncology, vol. 7, no. 5, pp. 251–
265, 2010.
[4] R. Pirker, F. J. F. Herth, K. M. Kerr et al., “Consensus for EGFR
mutation testing in non-small cell lung cancer: results from a
European workshop,” Journal of Thoracic Oncology, vol. 5, no.
10, pp. 1706–1713, 2010.
[5] B. W. Newsome andM. S. Ernstoff, “The clinical pharmacology
of therapeutic monoclonal antibodies in the treatment of
malignancy; have the magic bullets arrived?” British Journal of
Clinical Pharmacology, vol. 66, no. 1, pp. 6–19, 2008.
[6] N.Normanno, S. Tejpar, F.Morgillo, A.De Luca, E. VanCutsem,
and F. Ciardiello, “Implications for KRAS status and EGFR-
targeted therapies in metastatic CRC,” Nature Reviews Clinical
Oncology, vol. 6, no. 9, pp. 519–527, 2009.
[7] R. R. Raval, A. B. Sharabi, A. J. Walker, C. G. Drake, and
P. Sharma, “Tumor immunology and cancer immunotherapy:
summary of the 2013 SITC primer,” Journal for ImmunoTherapy
of Cancer, vol. 2, article 14, 2014.
[8] E. J. Lipson and C. G. Drake, “Ipilimumab: an anti-CTLA-4
antibody for metastatic melanoma,” Clinical Cancer Research,
vol. 17, no. 22, pp. 6958–6962, 2011.
[9] J. D.Wolchok, H. Kluger,M. K. Callahan et al., “Nivolumab plus
Ipilimumab in advanced melanoma,”The New England Journal
of Medicine, vol. 369, no. 2, pp. 122–133, 2013.
[10] E. M. Van Allen, N. Wagle, A. Sucker et al., “The genetic
landscape of clinical resistance to RAF inhibition in metastatic
melanoma,” Cancer Discovery, vol. 4, no. 1, pp. 94–109, 2014.
[11] T. G. Bivona, H. Hieronymus, J. Parker et al., “FAS and NF-
𝜅B signalling modulate dependence of lung cancers on mutant
EGFR,” Nature, vol. 471, no. 7339, pp. 523–526, 2011.
[12] P. B. Chapman, A. Hauschild, C. Robert et al., “Improved sur-
vival with vemurafenib in melanoma with BRAF V600E muta-
tion,”TheNew England Journal of Medicine, vol. 364, no. 26, pp.
2507–2516, 2011.
[13] A. Hauschild, J.-J. Grob, L. V. Demidov et al., “Dabrafenib
in BRAF-mutated metastatic melanoma: a multicentre, open-
label, phase 3 randomised controlled trial,”The Lancet, vol. 380,
no. 9839, pp. 358–365, 2012.
[14] N. Wagle, E. M. Van Allen, D. J. Treacy et al., “MAP kinase
pathway alterations in BRAF-mutant melanoma patients with
acquired resistance to combined RAF/MEK inhibition,” Cancer
Discovery, vol. 4, no. 1, pp. 61–68, 2013.
[15] J. Villanueva, J. R. Infante, C. Krepler et al., “Concurrent MEK2
mutation and BRAF amplification confer resistance to BRAF
and MEK inhibitors in melanoma,” Cell Reports, vol. 4, no. 6,
pp. 1090–1099, 2013.
[16] A. Marchetti, M. Del Grammastro, G. Filice et al., “Complex
mutations & subpopulations of deletions at exon 19 of EGFR
in NSCLC revealed by next generation sequencing: potential
clinical implications,” PLoS ONE, vol. 7, no. 7, Article ID e42164,
2012.
[17] A. Marchetti, A. Ardizzoni, M. Papotti et al., “Recommenda-
tions for the analysis of ALK gene rearrangements in non-
small-cell lung cancer: a consensus of the italian association
of medical oncology and the Italian society of pathology and
cytopathology,” Journal of Thoracic Oncology, vol. 8, no. 3, pp.
352–358, 2013.
[18] H. Shen and P. W. Laird, “Interplay between the cancer genome
and epigenome,” Cell, vol. 153, no. 1, pp. 38–55, 2013.
[19] L.G. Biesecker andN.B. Spinner, “A genomic viewofmosaicism
and human disease,” Nature Reviews Genetics, vol. 14, no. 5, pp.
307–320, 2013.
[20] J. G. Paez, P. A. Ja¨nne, J. C. Lee et al., “EGFR mutations in lung
cancer: correlation with clinical response to gefitinib therapy,”
Science, vol. 304, no. 5676, pp. 1497–1500, 2004.
[21] J. Malm, T. E. Fehniger, P. Danmyr et al., “Developments
in biobanking workflow standardization providing sample
integrity and stability,” Journal of Proteomics, vol. 95, pp. 38–45,
2013.
[22] G. da Cunha Santos, N. Liu,M.-S. Tsao, S. Kamel-Reid, K. Chin,
andW. R. Geddie, “Detection of EGFR and KRAS mutations in
fine-needle aspirates stored on whatman FTA cards: is this the
tool for biobanking cytological samples in the molecular era?”
Cancer Cytopathology, vol. 118, no. 6, pp. 450–456, 2010.
[23] S. Subramaniam,R.K.Thakur,V.K. Yadav, R.Nanda, S. Chowd-
hury, andA. Agrawal, “Lung cancer biomarkers: state of the art,”
Journal of Carcinogenesis, vol. 12, no. 3, 2013.
[24] M. G. Kris, R. B. Natale, R. S. Herbst et al., “Efficacy of
gefitinib, an inhibitor of the epidermal growth factor receptor
tyrosine kinase, in symptomatic patients with non-small cell
lung cancer: a randomized trial,” The Journal of the American
Medical Association, vol. 290, no. 16, pp. 2149–2158, 2003.
[25] A. Chi, S. Remick, and W. Tse, “EGFR inhibition in non-small
cell lung cancer: current evidence and future directions,”
Biomarker Research, vol. 1, article 2, 2013.
[26] G. R. Oxnard, A. Binder, and P. A. Ja¨nne, “New targetable onco-
genes in non-small-cell lung cancer,” Journal of Clinical Oncol-
ogy, vol. 31, no. 8, pp. 1097–1104, 2013.
[27] S. Liu, L.-C. Wu, J. Pang et al., “Sp1/NF𝜅B/HDAC/miR-29b
regulatory network in KIT-driven myeloid leukemia,” Cancer
Cell, vol. 17, no. 4, pp. 333–347, 2010.
Journal of Nanotechnology 15
[28] G. Iyer, A. J. Hanrahan,M. I.Milowsky et al., “Genome sequenc-
ing identifies a basis for everolimus sensitivity,” Science, vol. 338,
no. 6104, p. 221, 2012.
[29] J. Shendure and H. Ji, “Next-generation DNA sequencing,”
Nature Biotechnology, vol. 26, no. 10, pp. 1135–1145, 2008.
[30] B. M. Venkatesan and R. Bashir, “Nanopore sensors for nucleic
acid analysis,”NatureNanotechnology, vol. 6, no. 10, pp. 615–624,
2011.
[31] S. Valastyan and R. A.Weinberg, “Tumormetastasis: molecular
insights and evolving paradigms,” Cell, vol. 147, no. 2, pp. 275–
292, 2011.
[32] L.Wan, K. Pantel, and Y. Kang, “Tumormetastasis: moving new
biological insights into the clinic,” Nature Medicine, vol. 19, no.
11, pp. 1450–1464, 2013.
[33] D. F. Quail and J. A. Joyce, “Microenvironmental regulation of
tumor progression andmetastasis,”NatureMedicine, vol. 19, no.
11, pp. 1423–1437, 2013.
[34] L.-M. Postovit, N. V. Margaryan, E. A. Seftor et al., “Human
embryonic stem cell microenvironment suppresses the tumori-
genic phenotype of aggressive cancer cells,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 105, no. 11, pp. 4329–4334, 2008.
[35] F. G. Giancotti, “Mechanisms governing metastatic dormancy
and reactivation,” Cell, vol. 155, no. 4, pp. 750–764, 2013.
[36] J. Chou, J. H. Lin, A. Brenot, J.-W. Kim, S. Provot, and Z. Werb,
“GATA3 suppresses metastasis and modulates the tumour
microenvironment by regulating microRNA-29b expression,”
Nature Cell Biology, vol. 15, no. 2, pp. 201–213, 2013.
[37] Y. Zhang, P. Yang, T. Sun et al., “miR-126 and miR-126∗ repress
recruitment of mesenchymal stem cells and inflammatory
monocytes to inhibit breast cancer metastasis,” Nature Cell
Biology, vol. 15, no. 3, pp. 284–294, 2013.
[38] J. P. Thiery, “Epithelial-mesenchymal transitions in tumour
progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–454,
2002.
[39] D. M. Gonzalez and D. Medici, “Signaling mechanisms of the
epithelial-mesenchymal transition,” Science Signaling, vol. 7, no.
344, p. re8, 2014.
[40] L. A. Byers, L. Diao, J. Wang et al., “An epithelial-mesenchymal
transition gene signature predicts resistance to EGFR and PI3K
inhibitors and identifies Axl as a therapeutic target for overcom-
ing EGFR inhibitor resistance,”Clinical Cancer Research, vol. 19,
no. 1, pp. 279–290, 2013.
[41] Z. Zhang, J. C. Lee, L. Lin et al., “Activation of the AXL kinase
causes resistance to EGFR-targeted therapy in lung cancer,”
Nature Genetics, vol. 44, no. 8, pp. 852–860, 2012.
[42] D. C. Radisky and M. A. LaBarge, “Epithelial-mesenchymal
transition and the stem cell phenotype,” Cell Stem Cell, vol. 2,
no. 6, pp. 511–512, 2008.
[43] R. K. Ambasta, A. Sharma, and P. Kumar, “Nanoparticle medi-
ated targeting of VEGFR and cancer stem cells for cancer
therapy,” Vascular Cell, vol. 3, article 26, 2011.
[44] N. D. Marjanovic, R. A. Weinberg, and C. L. Chaffer, “Cell
plasticity and heterogeneity in cancer,” Clinical Chemistry, vol.
59, no. 1, pp. 168–179, 2013.
[45] S. J. Vidal, V. Rodriguez-Bravo, M. Galsky, C. Cordon-Cardo,
and J. Domingo-Domenech, “Targeting cancer stem cells to
suppress acquired chemotherapy resistance,” Oncogene, vol. 33,
no. 36, pp. 4451–4463, 2014.
[46] C. E. Eyler and J. N. Rich, “Survival of the fittest: cancer stem
cells in therapeutic resistance and angiogenesis,” Journal of
Clinical Oncology, vol. 26, no. 17, pp. 2839–2845, 2008.
[47] H. Lou and M. Dean, “Targeted therapy for cancer stem cells:
the patched pathway and ABC transporters,” Oncogene, vol. 26,
no. 9, pp. 1357–1360, 2007.
[48] R. Morrison, S. M. Schleicher, Y. Sun et al., “Targeting the
mechanisms of resistance to chemotherapy and radiotherapy
with the cancer stem cell hypothesis,” Journal of Oncology, vol.
2011, Article ID 941876, 13 pages, 2011.
[49] S. Vinogradov and X. Wei, “Cancer stem cells and drug
resistance: the potential of nanomedicine,” Nanomedicine, vol.
7, no. 4, pp. 597–615, 2012.
[50] B. T. Kawasaki, E. M. Hurt, T. Mistree, and W. L. Farrar,
“Targeting cancer stem cells with phytochemicals,” Molecular
Interventions, vol. 8, no. 4, pp. 174–184, 2008.
[51] P. B.Gupta, T. T.Onder,G. Jiang et al., “Identification of selective
inhibitors of cancer stem cells by high-throughput screening,”
Cell, vol. 138, no. 4, pp. 645–659, 2009.
[52] Y. Zhao, D. Y. Alakhova, and A. V. Kabanov, “Can
nanomedicines kill cancer stem cells?” Advanced Drug
Delivery Reviews, vol. 65, no. 13-14, pp. 1763–1783, 2013.
[53] S. B. Baylin and P. A. Jones, “A decade of exploring the cancer
epigenome—biological and translational implications,” Nature
Reviews Cancer, vol. 11, no. 10, pp. 726–734, 2011.
[54] J. Sana, P. Faltejskova, M. Svoboda, and O. Slaby, “Novel classes
of non-coding RNAs and cancer,” Journal of Translational
Medicine, vol. 10, article 103, 2012.
[55] A. Hui, C. How, E. Ito, and F.-F. Liu, “Micro-RNAs as diagnostic
or prognostic markers in human epithelial malignancies,” BMC
Cancer, vol. 11, article 500, 2011.
[56] S. Fukushige and A. Horii, “DNA methylation in cancer: a
gene silencing mechanism and the clinical potential of its
biomarkers,” Tohoku Journal of Experimental Medicine, vol. 229,
no. 3, pp. 173–185, 2013.
[57] P. A. Jones, “Functions of DNAmethylation: islands, start sites,
gene bodies and beyond,” Nature Reviews Genetics, vol. 13, no.
7, pp. 484–492, 2012.
[58] A. G. Knudson Jr., “Mutation and cancer: statistical study of
retinoblastoma,”Proceedings of theNational Academy of Sciences
of the United States of America, vol. 68, no. 4, pp. 820–823, 1971.
[59] G. A. Calin and C. M. Croce, “MicroRNA signatures in human
cancers,” Nature Reviews Cancer, vol. 6, no. 11, pp. 857–866,
2006.
[60] S. Liu, “Epigenetics advancing personalized nanomedicine in
cancer therapy,” Advanced Drug Delivery Reviews, vol. 64, no.
13, pp. 1532–1543, 2012.
[61] T. F. Gajewski, “Molecular profiling of melanoma and the
evolution of patient-specific therapy,” Seminars inOncology, vol.
38, no. 2, pp. 236–242, 2011.
[62] K. L. Nathanson, “Using genetics and genomics strategies to
personalize therapy for cancer: focus on melanoma,” Biochemi-
cal Pharmacology, vol. 80, no. 5, pp. 755–761, 2010.
[63] P. V. Jithesh, J. M. Risk, A. G. Schache et al., “The epigenetic
landscape of oral squamous cell carcinoma,” British Journal of
Cancer, vol. 108, no. 2, pp. 370–379, 2013.
[64] J. R. Schoenborn, P. Nelson, and M. Fang, “Genomic profiling
defines subtypes of prostate cancer with the potential for
therapeutic stratification,” Clinical Cancer Research, vol. 19, no.
15, pp. 4058–4066, 2013.
[65] D. S. Uppal and S. M. Powell, “Genetics/genomics/proteomics
of gastric adenocarcinoma,” Gastroenterology Clinics of North
America, vol. 42, no. 2, pp. 241–260, 2013.
16 Journal of Nanotechnology
[66] C. P. Lange and P. W. Laird, “Clinical applications of DNA
methylation biomarkers in colorectal cancer,” Epigenomics, vol.
5, no. 2, pp. 105–108, 2013.
[67] H. Kim, K. Kim, S. J. Yu et al., “Development of biomarkers for
screening hepatocellular carcinoma using global data mining
and multiple reaction monitoring,” PLoS ONE, vol. 8, no. 5,
Article ID e63468, 2013.
[68] M. Chmelarova´, E. Dvora´kova´, J. Sˇpacek, J. Laco, M. MZˇik, and
V. Palicka, “Promoter methylation of GATA4, WIF1, NTRK1
and other selected tumour suppressor genes in ovarian cancer,”
Folia Biologica, vol. 59, no. 2, pp. 87–92, 2013.
[69] A. I. Ojesina, L. Lichtenstein, S. S. Freeman et al., “Landscape
of genomic alterations in cervical carcinomas,”Nature, vol. 506,
no. 7488, pp. 371–375, 2013.
[70] A. Q. van Hoesel, Y. Sato, D. A. Elashoff et al., “Assessment
of DNA methylation status in early stages of breast cancer
development,” British Journal of Cancer, vol. 108, no. 10, pp.
2033–2038, 2013.
[71] A. I. Oliveira, C. Jero´nimo, and R. Henrique, “Moving forward
in bladder cancer detection and diagnosis: the role of epigenetic
biomarkers,” Expert Review ofMolecular Diagnostics, vol. 12, no.
8, pp. 871–878, 2012.
[72] S. Markopoulou, G. Nikolaidis, and T. Liloglou, “DNA methy-
lation biomarkers in biological fluids for early detection of
respiratory tract cancer,” Clinical Chemistry and Laboratory
Medicine, vol. 50, no. 10, pp. 1723–1731, 2012.
[73] K. A. Heichman and J. D.Warren, “DNAmethylation biomark-
ers and their utility for solid cancer diagnostics,” Clinical
Chemistry and Laboratory Medicine, vol. 50, no. 10, pp. 1707–
1721, 2012.
[74] J. K. Samuelsson, S. Alonso, F. Yamamoto, and M. Perucho,
“DNA fingerprinting techniques for the analysis of genetic
and epigenetic alterations in colorectal cancer,” Mutation
Research/Fundamental and Molecular Mechanisms of Mutagen-
esis, vol. 693, no. 1-2, pp. 61–76, 2010.
[75] G. S. Inamdar, S. V.Madhunapantula, andG. P. Robertson, “Tar-
geting theMAPK pathway in melanoma: why some approaches
succeed and other fail,” Biochemical Pharmacology, vol. 80, no.
5, pp. 624–637, 2010.
[76] J. A. Gasche and A. Goel, “Epigenetic mechanisms in oral
carcinogenesis,” Future Oncology, vol. 8, no. 11, pp. 1407–1425,
2012.
[77] D. Hanahan and R. A.Weinberg, “Hallmarks of cancer: the next
generation,” Cell, vol. 144, no. 5, pp. 646–674, 2011.
[78] J. B. Rawson and B. Bapat, “Epigenetic biomarkers in colorectal
cancer diagnostics,”Expert Review ofMolecular Diagnostics, vol.
12, no. 5, pp. 499–509, 2012.
[79] M. Berg and K. Søreide, “Genetic and epigenetic traits as
biomarkers in colorectal cancer,” International Journal of Molec-
ular Sciences, vol. 12, no. 12, pp. 9426–9439, 2011.
[80] M.-A. Song, M. Tiirikainen, S. Kwee, G. Okimoto, H. Yu, and L.
L. Wong, “Elucidating the landscape of aberrant DNA methy-
lation in hepatocellular carcinoma,” PLoS ONE, vol. 8, no. 2,
Article ID e55761, 2013.
[81] A. Fujimoto, Y. Totoki, T. Abe et al., “Whole-genome sequenc-
ing of liver cancers identifies etiological influences on mutation
patterns and recurrent mutations in chromatin regulators,”
Nature Genetics, vol. 44, no. 7, pp. 760–764, 2012.
[82] C. Ozen, G. Yildiz, A. T. Dagcan et al., “Genetics and epigenetics
of liver cancer,” New Biotechnology, vol. 30, no. 4, pp. 381–384,
2013.
[83] G. Diaz, M. Melis, A. Tice et al., “Identification of microRNAs
specifically expressed in hepatitis C virus-associated hepatocel-
lular carcinoma,” International Journal of Cancer, vol. 133, no. 4,
pp. 816–824, 2013.
[84] L. E. De Faveri, C. D. Hurst, F. M. Platt et al., “Putative tumour
suppressor gene necdin is hypermethylated and mutated in
human cancer,” British Journal of Cancer, vol. 108, no. 6, pp.
1368–1377, 2013.
[85] Y. Gui, G. Guo, Y. Huang et al., “Frequent mutations of
chromatin remodeling genes in transitional cell carcinoma of
the bladder,” Nature Genetics, vol. 43, no. 9, pp. 875–878, 2011.
[86] B. R. Druliner, J. A. Fincher, B. S. Sexton et al., “Chromatin
patterns associated with lung adenocarcinoma progression,”
Cell Cycle, vol. 12, no. 10, pp. 1536–1543, 2013.
[87] P. K. Vogt, “Retroviral oncogenes: a historical primer,” Nature
Reviews Cancer, vol. 12, no. 9, pp. 639–648, 2012.
[88] T. Soussi, “Advances in carcinogenesis: a historical perspective
from observational studies to tumor genome sequencing and
TP53 mutation spectrum analysis,” Biochimica et Biophysica
Acta—Reviews on Cancer, vol. 1816, no. 2, pp. 199–208, 2011.
[89] A. J. Bass, M. S. Lawrence, L. E. Brace et al., “Genomic sequenc-
ing of colorectal adenocarcinomas identifies a recurrent VTI1A-
TCF7L2 fusion,” Nature Genetics, vol. 43, no. 10, pp. 964–970,
2011.
[90] A. Kreso, C. A. O’Brien, P. van Galen et al., “Variable clonal
repopulation dynamics influence chemotherapy response in
colorectal cancer,” Science, vol. 339, no. 6119, pp. 543–548, 2013.
[91] D. Singh, J. M. Chan, P. Zoppoli et al., “Transforming fusions
of FGFR and TACC genes in human glioblastoma,” Science, vol.
337, no. 6099, pp. 1231–1235, 2012.
[92] S. Seton-Rogers, “Glioblastoma: transforming fusions induce
aneuploidy,” Nature Reviews Cancer, vol. 12, no. 9, article 585,
2012.
[93] V. Frattini, V. Trifonov, J. M. Chan et al., “The integrated
landscape of driver genomic alterations in glioblastoma,”Nature
Genetics, vol. 45, no. 10, pp. 1141–1149, 2013.
[94] P. A. Northcott, D. J. Shih, J. Peacock et al., “Subgroup-specific
structural variation across 1,000 medulloblastoma genomes,”
Nature, vol. 488, no. 7409, pp. 49–56, 2012.
[95] G. P. Tonini, A. Nakagawara, and F. Berthold, “Towards a
turning point of neuroblastoma therapy,” Cancer Letters, vol.
326, no. 2, pp. 128–134, 2012.
[96] M. Capasso, M. Devoto, C. Hou et al., “Common variations
in BARD1 influence susceptibility to high-risk neuroblastoma,”
Nature Genetics, vol. 41, no. 6, pp. 718–723, 2009.
[97] K. Wang, S. J. Diskin, H. Zhang et al., “Integrative genomics
identifies LMO1 as a neuroblastoma oncogene,”Nature, vol. 469,
no. 7329, pp. 216–220, 2011.
[98] M. Sausen, R. J. Leary, S. Jones et al., “Integrated genomic anal-
yses identify ARID1A and ARID1B alterations in the childhood
cancer neuroblastoma,”Nature Genetics, vol. 45, no. 1, pp. 12–17,
2013.
[99] B. Banelli, D. F. Merlo, G. Allemanni, A. Forlani, and M.
Romani, “Clinical potentials of methylator phenotype in stage
4 high-risk neuroblastoma: an open challenge,” PLoS ONE, vol.
8, no. 5, Article ID e63253, 2013.
[100] L.VanNeste, J. G.Herman,G.Otto, J.W. Bigley, J. I. Epstein, and
W. Van Criekinge, “The epigenetic promise for prostate cancer
diagnosis,” Prostate, vol. 72, no. 11, pp. 1248–1261, 2012.
[101] H.-Y. Yoon, Y.-W. Kim, H. W. Kang et al., “Pyrosequencing
analysis of APC methylation level in human prostate tissues:
Journal of Nanotechnology 17
a molecular marker for prostate cancer,” Korean Journal of
Urology, vol. 54, no. 3, pp. 194–198, 2013.
[102] M. Ilie, V. Hofman, E. Long et al., “Current challenges for
detection of circulating tumor cells and cell-free circulating
nucleic acids, and their characterization in non-small cell
lung carcinoma patients. What is the best blood substrate for
personalized medicine?” Annals of Translational Medicine, vol.
2, no. 11, p. 107, 2014.
[103] M. Ilie, V. Hofman, E. Long-Mira et al., “‘Sentinel’ circulating
tumor cells allow early diagnosis of lung cancer in patients with
Chronic obstructive pulmonary disease,” PLoS ONE, vol. 9, no.
10, Article ID e111597, 2014.
[104] Y. J. Zhao,Q. Ju, andG.C. Li, “Tumormarkers for hepatocellular
carcinoma,” Molecular and Clinical Oncology, vol. 1, no. 4, pp.
593–598, 2013.
[105] S.-Y. Liao, O. N. Aurelio, K. Jan, J. Zavada, and E. J. Stanbridge,
“Identification of the MN/CA9 protein as a reliable diagnostic
biomarker of clear cell carcinoma of the kidney,” Cancer
Research, vol. 57, no. 14, pp. 2827–2831, 1997.
[106] J. J. Morrissey, A. N. London, J. Luo, and E. D. Kharasch,
“Urinary biomarkers for the early diagnosis of kidney cancer,”
Mayo Clinic Proceedings, vol. 85, no. 5, pp. 413–421, 2010.
[107] D. SuKim, Y.D. Choi,M.Moon et al., “Composite three-marker
assay for early detection of kidney cancer,”Cancer Epidemiology
Biomarkers and Prevention, vol. 22, no. 3, pp. 390–398, 2013.
[108] H. Abe and T. Kamai, “Recent advances in the treatment
of metastatic renal cell carcinoma,” International Journal of
Urology, vol. 20, no. 10, pp. 944–955, 2013.
[109] S. G. C. Kroeze, A. M. Bijenhof, J. L. H. R. Bosch, and J. J. M.
Jans, “Diagnostic and prognostic tissuemarkers in clear cell and
papillary renal cell carcinoma,” Cancer Biomarkers, vol. 7, no. 6,
pp. 261–268, 2010.
[110] L. J. Costa and H. A. Drabkin, “Renal cell carcinoma: new
developments in molecular biology and potential for targeted
therapies,” Oncologist, vol. 12, no. 12, pp. 1404–1415, 2007.
[111] M. Wehland, J. Bauer, N. E. Magnusson, M. Infanger, and D.
Grimm, “Biomarkers for anti-angiogenic therapy in cancer,”
International Journal of Molecular Sciences, vol. 14, no. 5, pp.
9338–9364, 2013.
[112] W.G. Kaelin Jr., “The vonHippel-Lindau tumor suppressor pro-
tein and clear cell renal carcinoma,” Clinical Cancer Research,
vol. 13, no. 2, part 2, pp. 680s–684s, 2007.
[113] Cancer Genome Atlas Research Network, “Comprehensive
molecular characterization of clear cell renal cell carcinoma,”
Nature, vol. 499, no. 7456, pp. 43–49, 2013.
[114] A.A.Hakimi, I. Ostrovnaya, B. Reva et al., “Adverse outcomes in
clear cell renal cell carcinoma withmutations of 3p21 epigenetic
regulators BAP1 and SETD2: a report byMSKCC and the KIRC
TCGA research network,” Clinical Cancer Research, vol. 19, no.
12, pp. 3259–3267, 2013.
[115] P. S. Mitchell, R. K. Parkin, E. M. Kroh et al., “Circulating
microRNAs as stable blood-based markers for cancer detec-
tion,” Proceedings of the National Academy of Sciences of the
United States of America, vol. 105, no. 30, pp. 10513–10518, 2008.
[116] C. H. Lawrie, S. Gal, H. M. Dunlop et al., “Detection of
elevated levels of tumour-associated microRNAs in serum of
patients with diffuse large B-cell lymphoma,” British Journal of
Haematology, vol. 141, no. 5, pp. 672–675, 2008.
[117] H. Qu, W. Xu, Y. Huang, and S. Yang, “Circulating miRNAs:
promising biomarkers of human cancer,” Asian Pacific Journal
of Cancer Prevention, vol. 12, no. 5, pp. 1117–1125, 2011.
[118] S. Valastyan and R. A. Weinberg, “MicroRNAs: crucial multi-
tasking components in the complex circuitry of tumormetasta-
sis,” Cell Cycle, vol. 8, no. 21, pp. 3506–3512, 2009.
[119] D. Zheng, S. Haddadin, Y. Wang et al., “Plasma microRNAs as
novel biomarkers for early detection of lung cancer,” Interna-
tional Journal of Clinical and Experimental Pathology, vol. 4, no.
6, pp. 575–586, 2011.
[120] H. Zheng, L. Zhang, Y. Zhao et al., “Plasma miRNAs as
diagnostic and prognostic biomarkers for ovarian cancer,” PLoS
ONE, vol. 8, no. 11, Article ID e77853, 2013.
[121] Y. Zhang, D. Yang, L. Weng, and L. Wang, “Early lung cancer
diagnosis by biosensors,” International Journal of Molecular
Sciences, vol. 14, no. 8, pp. 15479–15509, 2013.
[122] M.A. Cortez, J.W.Welsh, andG.A. Calin, “CirculatingMicroR-
NAs as noninvasive biomarkers in breast cancer,” Recent Results
in Cancer Research, vol. 195, pp. 151–161, 2012.
[123] H. Schwarzenbach, N. Nishida, G. A. Calin, and K. Pantel,
“Clinical relevance of circulating cell-free microRNAs in can-
cer,”Nature Reviews Clinical Oncology, vol. 11, no. 3, pp. 145–156,
2014.
[124] E. Heitzer, P. Ulz, and J. B. Geigl, “Circulating tumor DNA as a
liquid biopsy for cancer,” Clinical Chemistry, vol. 61, no. 1, pp.
112–123, 2015.
[125] D. Peer, J. M. Karp, S. Hong, O. C. Farokhzad, R. Margalit, and
R. Langer, “Nanocarriers as an emerging platform for cancer
therapy,” Nature Nanotechnology, vol. 2, no. 12, pp. 751–760,
2007.
[126] D. J. Bharali and S. A. Mousa, “Emerging nanomedicines for
early cancer detection and improved treatment: current per-
spective and future promise,” Pharmacology and Therapeutics,
vol. 128, no. 2, pp. 324–335, 2010.
[127] Y.-E. Choi, J.-W. Kwak, and J. W. Park, “Nanotechnology for
early cancer detection,” Sensors, vol. 10, no. 1, pp. 428–455, 2010.
[128] R. Ranganathan, S.Madanmohan,A.Kesavan et al., “Nanomed-
icine: towards development of patient-friendly drug-delivery
systems for oncological applications,” International Journal of
Nanomedicine, vol. 7, pp. 1043–1060, 2012.
[129] Y. Hu, D. H. Fine, E. Tasciotti, A. Bouamrani, and M. Ferrari,
“Nanodevices in diagnostics,” Wiley Interdisciplinary Reviews:
Nanomedicine and Nanobiotechnology, vol. 3, no. 1, pp. 11–32,
2011.
[130] E.-K. Lim, E. Jang, K. Lee, S. Haam, and Y.-M.Huh, “Delivery of
cancer therapeutics using nanotechnology,” Pharmaceutics, vol.
5, no. 2, pp. 294–317, 2013.
[131] I. E. Tothill, “Biosensors for cancer markers diagnosis,” Semi-
nars in Cell and Developmental Biology, vol. 20, no. 1, pp. 55–62,
2009.
[132] K. K. Jain, “Advances in the field of nanooncology,” BMC
Medicine, vol. 8, article 83, 2010.
[133] X.Qian, X.-H. Peng, D.O. Ansari et al., “In vivo tumor targeting
and spectroscopic detection with surface-enhanced Raman
nanoparticle tags,” Nature Biotechnology, vol. 26, no. 1, pp. 83–
90, 2008.
[134] J. Aaron, N. Nitin, K. Travis et al., “Plasmon resonance coupling
of metal nanoparticles for molecular imaging of carcinogenesis
in vivo,” Journal of Biomedical Optics, vol. 12, no. 3, Article ID
034007, 2007.
[135] I. H. El-Sayed, X. Huang, and M. A. El-Sayed, “Selective laser
photo-thermal therapy of epithelial carcinomausing anti-EGFR
antibody conjugated gold nanoparticles,” Cancer Letters, vol.
239, no. 1, pp. 129–135, 2006.
18 Journal of Nanotechnology
[136] X. Liu, Q. Dai, L. Austin et al., “A one-step homogeneous
immunoassay for cancer biomarker detection using gold
nanoparticle probes coupled with dynamic light scattering,”
Journal of the American Chemical Society, vol. 130, no. 9, pp.
2780–2782, 2008.
[137] V. Mani, B. V. Chikkaveeraiah, V. Patel, J. S. Gutkind, and
J. F. Rusling, “Ultrasensitive immunosensor for cancer bio-
marker proteins using gold nanoparticle film electrodes and
multienzyme-particle amplification,”ACSNano, vol. 3, no. 3, pp.
585–594, 2009.
[138] M. Soster, R. Juris, S. Bonacchi et al., “Targeted dual-color silica
nanoparticles provide univocal identification of micrometas-
tases in preclinical models of colorectal cancer,” International
Journal of Nanomedicine, vol. 7, pp. 4797–4807, 2012.
[139] H. Lee, E. Sun, D. Ham, and R. Weissleder, “Chip-NMR
biosensor for detection and molecular analysis of cells,” Nature
Medicine, vol. 14, no. 8, pp. 869–874, 2008.
[140] S. Y. Madani, F. Shabani, M. V. Dwek, and A. M. Seifalian,
“Conjugation of quantum dots on carbon nanotubes for
medical diagnosis and treatment,” International Journal of
Nanomedicine, vol. 8, pp. 941–950, 2013.
[141] J. Clarke, H.-C. Wu, L. Jayasinghe, A. Patel, S. Reid, and H.
Bayley, “Continuous base identification for single-molecule
nanopore DNA sequencing,”Nature Nanotechnology, vol. 4, no.
4, pp. 265–270, 2009.
[142] M. Das, D. Mishra, P. Dhak et al., “Biofunctionalized, phos-
phonate-grafted, ultrasmall iron oxide nanoparticles for com-
bined targeted cancer therapy and multimodal imaging,” Small,
vol. 5, no. 24, pp. 2883–2893, 2009.
[143] S. K. Arya and S. Bhansali, “Lung cancer and its early detection
using biomarker-based biosensors,” Chemical Reviews, vol. 111,
no. 11, pp. 6783–6809, 2011.
[144] J. C. Brase, D. Wuttig, R. Kuner, and H. Su¨ltmann, “Serum
microRNAs as non-invasive biomarkers for cancer,” Molecular
Cancer, vol. 9, p. 306, 2010.
[145] D. Barh, A. Carpi, M. Verma et al., Cancer Biomarkers: Minimal
and Noninvasive Early Diagnosis and Prognosis, CRC Press,
Boca Raton, Fla, USA, 2014.
[146] K. T. Adams, “Ups and downs at ASCO 2014,” Managed Care,
vol. 23, no. 8, pp. 50–52, 2014.
[147] D. Siolas and G. J. Hannon, “Patient-derived tumor xenografts:
transforming clinical samples into mouse models,” Cancer
Research, vol. 73, no. 17, pp. 5315–5319, 2013.
[148] A. Gdowski, A. P. Ranjan, A. Mukerjee, and J. K. Vishwanatha,
“Nanobiosensors: role in cancer detection and diagnosis,”
Advances in ExperimentalMedicine andBiology, vol. 807, pp. 33–
58, 2014.
[149] L. Saenz del Burgo, J. L. Pedraz, and G. Orive, “Advanced
nanovehicles for cancer management,” Drug Discovery Today,
vol. 19, no. 10, pp. 1659–1670, 2014.
[150] V. Sanna, N. Pala, and M. Sechi, “Targeted therapy using
nanotechnology: focus on cancer,” International Journal of
Nanomedicine, vol. 9, no. 1, pp. 467–483, 2014.
[151] J. Chen, R. Shao, X. D. Zhang et al., “Applications of nanotech-
nology for melanoma treatment, diagnosis, and theranostics,”
International Journal of Nanomedicine, vol. 8, pp. 2677–2688,
2013.
[152] C. Esposito, A. Crema, A. Ponzetto, G. Murtas, and G. Carloni,
“Multifunctional anti-cancer nano-platforms are moving to
clinical trials,” Current Drug Metabolism, vol. 14, no. 5, pp. 583–
604, 2013.
[153] M. S. Muthu, D. T. Leong, L. Mei, and S.-S. Feng, “Nanotheran-
ostics—application and further development of nanomedicine
strategies for advanced theranostics,”Theranostics, vol. 4, no. 6,
pp. 660–677, 2014.
[154] A. R. Burke, R.N. Singh,D. L. Carroll, F.M. Torti, and S.V. Torti,
“Targeting cancer stem cells with nanoparticle-enabled thera-
pies,” Journal of Molecular Biomarkers & Diagnosis, supplement
8, 2012.
[155] M. K. Yu, J. Park, and S. Jon, “Targeting strategies for multi-
functional nanoparticles in cancer imaging and therapy,”Ther-
anostics, vol. 2, no. 1, pp. 3–44, 2012.
Submit your manuscripts at
http://www.hindawi.com
Scientifica
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Corrosion
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Polymer Science
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Ceramics
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Composites
Journal of
Nanoparticles
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
International Journal of
Biomaterials
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Nanoscience
Journal of
Textiles
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Journal of
Nanotechnology
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Crystallography
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Coatings
Journal of
Advances in 
Materials Science and Engineering
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Smart Materials 
Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Metallurgy
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Materials
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
N
an
om
at
er
ia
ls
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal ofNanomaterials
